Good News Digest

health and healing

Teenager no longer needs transfusions after gene-editing treatment

Germany

Four months after receiving a gene-editing treatment, 19-year-old Mohammad no longer depends on blood transfusions, according to Berlin’s Charité hospital. The hospital says his treatment marks Germany’s first use of the CRISPR-based therapy in routine care, rather than a clinical trial.

Mohammad has beta-thalassaemia, an inherited disorder that disrupts production of haemoglobin, the protein in red blood cells that carries oxygen. People with severe disease need transfusions roughly every three weeks, with potentially serious side effects over time.

The treatment, sold as Casgevy, uses a patient’s own blood-forming stem cells. These are edited in a laboratory so they can produce a form of haemoglobin normally made before birth. Mohammad received the modified cells in May; his haemoglobin level is now within the normal range.

The procedure is demanding: patients first need high-dose chemotherapy, which can cause liver damage and infertility. Long-term safety and effectiveness remain uncertain, and treated patients must be monitored for 15 years. The therapy has been conditionally approved in the European Union since 2024 for certain patients aged 12 and over.

For now, the change is practical as well as medical: Charité says Mohammad can lead a normal daily life and wants to begin vocational training.

Sources

  1. DIE WELTMedizinischer Durchbruch: Charité-Ärzte heilen erstmals einen Patienten in Deutschland mit der Genschere
  2. Der TagesspiegelEr braucht keine Transfusionen mehr: Charité behandelt erstmals nach der Zulassung einen Patienten mit der Genschere

Reporting notes

Where this came from

Charité

Der Tagesspiegel uses “wie die Klinik mitteilt” and “laut Charité”; DIE WELT uses “nach Charité-Angaben” and “hieß es von der Charité weiter.” Their shared hospital attribution should not be treated as independent confirmation.

Deutschen Ärzteblatt

Der Tagesspiegel introduces the US and UK price figures with “Laut dem Deutschen Ärzteblatt”; this is a separate disclosed origin for ancillary cost information.

Joachim Kunz

DIE WELT states that Joachim Kunz of Universitätsklinikum Heidelberg “erklärte einmal” that the therapy is complex and resource-intensive; the article does not present this as a new interview.